Variant: rs121913428 

    present in Gene: EGFR
    present in Chromosome: 7
    Position on Chromosome: 55174015
    Alleles of this Variant: G/A;C

rs121913428 in EGFR gene and Adenocarcinoma of lung (disorder) PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913428 in EGFR gene and Glioblastoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913428 in EGFR gene and Non-Small Cell Lung Carcinoma PMID 15710947 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

PMID 16115929 2005 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 15738541 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

PMID 22753918 2012 Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PMID 15329413 2004 "EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."

PMID 19922469 2010 Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

PMID 23102728 2013 MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.

PMID 16011858 2005 Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

PMID 21531810 2011 "Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."

PMID 2302402 1990 Effects of marine oil-enriched diets on guinea pig megakaryocyte and platelet lipids: effects on thromboxane synthesis and platelet function.

PMID 20479403 2010 Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

PMID 15118125 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

PMID 15118073 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

PMID 23242437 2013 Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

PMID 23945392 2013 Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

PMID 18458038 2008 First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

rs121913428 in EGFR gene and Squamous cell carcinoma of lung PMID 22753918 2012 Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PMID 23102728 2013 MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.